Some studies sponsored by Novo Nordisk suggest that semaglutide may actually help reduce the risk of kidney disease over the long term. But there have also been reports of individuals taking GLP-1 ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

You should inject semaglutide subcutaneously, that is, just under the surface of your skin. You can rotate injections between your stomach, upper arm, and thigh. Semaglutide is a prescription type ...

Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock ... a small study that suggests that "low doses" of semaglutide (the active ingredient in Ozempic) may be helpful ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

A new study showed that semaglutide may help with alcohol use ... of the American Medical Association Psychiatry. In May 2024, Novo Nordisk, the manufacturer of Ozempic, announced it would study ...

Novo Nordisk says Wegovy and Ozempic are not interchangeable. Semaglutide is a synthetic version of a hormone known as GLP-1, which the body releases into the intestine when people eat food ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

CARDOL contains sotalol hydrochloride as the active ingredient which belongs to a group of medicines called beta-blockers. It works by changing the body's response to some nerve impulses ...

Novo Nordisk’s blockbuster weight-loss therapy semaglutide—sold as Ozempic for type 2 diabetes and Wegovy for chronic weight management—could potentially help people curb their cravings for and ...